Global health challenges
Partnering with the global vaccines community towards universal immunization
Together with our partners, our members are united by a common challenge to grow the “vaccinated community” to save lives, improve health, and ensure long-term prosperity through vaccines and immunization.
- The pathway towards universal immunization is driven by the global vaccines community, an interdependent network of organizations and stakeholders including vaccine manufacturers.
- Our members can make a unique and vital contribution to that collective effort, by scaling up supply and developing new and improved vaccines, as well working to ensure vaccines reach those communities which need them most.
Value of vaccination
Immunization not only saves lives and improves health; it also unlocks the potential of the community. Parents can be more productive if they spend less time taking care of their sick children. Children achieve more in school if they are healthy. A vaccinated community is not only healthier; it is stronger and more productive.
The global vaccines community is a network of interdependent stakeholders, each bringing vital resources – human, technical and financial – to the joint effort to protect people against infectious diseases through immunization. Our partnerships enable us to deliver innovation and scale to the supply and development of vaccines, and make a meaningful and sustained contribution to this collective effort.
As a group of private sector companies, our members are guided by a conviction that our approach as businesses can power our contribution to realizing the ambition of universal immunization and at the same time create value for our investors. Our business models maintain investment that ensures the production and reliable supply of vaccines for today, and enable the development of improved vaccines and new vaccine technologies for tomorrow.
There is a positive correlation between immunization and the quality of learning. For example a study in the Philippines established that the immunization of children with DTPii, Polio, TB and measles vaccines by the age of two yielded improved cognitive function at age 10.
USD 63 billion
potential cost savings from rolling out pneumococcal, Hib, and rotavirus vaccines in the world’s
infants worldwide are still missing out on basic vaccines (DTP3) that cost 19 cents a dose